Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 17986
Country/Region: Tanzania
Year: 2016
Main Partner: Ariel Glaser Pediatric AIDS Healthcare Initiative
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $25,873,992 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $910,675
Care: Pediatric Care and Support (PDCS) $499,649
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $84,595
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $5,803,573
Treatment: Adult Treatment (HTXS) $16,906,906
Treatment: Pediatric Treatment (PDTX) $1,668,594
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 2,459
GEND_GBV Age/Sex: <10 Male 2017 2,244
GEND_GBV Age/Sex: 10-14 Female 2017 3,958
GEND_GBV Age/Sex: 10-14 Male 2017 2,756
GEND_GBV Age/Sex: 15-19 Female 2017 2,047
GEND_GBV Age/Sex: 15-19 male 2017 1,992
GEND_GBV Age/Sex: 20-24 Female 2017 1,568
GEND_GBV Age/Sex: 20-24 Male 2017 1,295
GEND_GBV Age/Sex: 25-49 Female 2017 1,987
GEND_GBV Age/Sex: 25-49 Male 2017 1,659
GEND_GBV Age/Sex: 50+ Female 2017 237
GEND_GBV Age/Sex: 50+ Male 2017 189
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 930
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 14,920
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 7,471
GEND_GBV Number of people receiving post-GBV care 2017 22,391
GEND_GBV Sum of Age/Sex Disaggregates 2017 11,417
HTS_TST Age/sex: <1 2017 2,844
HTS_TST Age/sex: 1-9 2017 14,202
HTS_TST Age/sex: 10-14 Female 2017 1,061
HTS_TST Age/sex: 10-14 Male 2017 4,283
HTS_TST Age/sex: 15-19 Female 2017 3,033
HTS_TST Age/sex: 15-19 Male 2017 788
HTS_TST Age/sex: 20-24 Female 2017 8,772
HTS_TST Age/sex: 20-24 Male 2017 2,738
HTS_TST Age/sex: 25-49 Female 2017 36,533
HTS_TST Age/sex: 25-49 Male 2017 28,288
HTS_TST Age/sex: 50+ Female 2017 6,539
HTS_TST Age/sex: 50+ Male 2017 7,987
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 64,315
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 103,560
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 533,735
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 199,714
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 1,018,392
HTS_TST Service Delivery Point (Facility): Inpatient 2017 24,983
HTS_TST Service Delivery Point (Facility): Other PITC 2017 20,716
HTS_TST Service Delivery Point (Facility): Outpatient 2017 259,729
HTS_TST Service Delivery Point (Facility): Pediatric 2017 168,100
HTS_TST Service Delivery Point (Facility): PMTCT 2017 542,705
HTS_TST Service Delivery Point (Facility): VMMC 2017 2,170
HTS_TST Sum of Age/Sex disaggregates 2017 100,022
HTS_TST Sum of Aggregated Age/Sex <15 2017 167,875
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 733,449
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 901,324
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 11
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 18
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 200
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 37
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 589
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 120
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 2,366
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 1,214
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 415
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 340
HTS_TST_POS Test Result by Age: Positive: <1 2017 13
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 137
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1,229
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1,404
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 21,789
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 9,314
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 2
LAB_PT CD4: Number of laboratories that perform this testing 2017 8
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 35
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 35
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 53
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 3
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 6
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 1
PMTCT_ART Already on ART at beginning of current pregnancy 2017 4,821
PMTCT_ART New on ART 2017 12,810
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 442,889
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 11,950
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 5,690
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 138
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 271
PMTCT_EID Sum of Infant Age disaggregates 2017 17,640
PMTCT_STAT By: Known positives at entry 2017 5,066
PMTCT_STAT By: Number of new positives identified 2017 13,485
PMTCT_STAT Number of new ANC and L&D clients 2017 466,201
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 442,889
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: <15 2017 35
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 70
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 167
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 209
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 1
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: <15 2017 108
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 235
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 505
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 673
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 4
PMTCT_STAT Sum of Positives Status disaggregates 2017 18,551
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 3,379
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 7,019
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 14,615
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 16,264
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 50+ 2017 90
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 3,355
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 49
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 2,951
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 355
TB_SCREENDX Screen Result: Screened Positive for TB 2017 3,355
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 135,679
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 66,020
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 8,780
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 7,277
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 217,756
TX_CURR Age/Sex: <1 2017 52
TX_CURR Age/Sex: <1-9 2017 1,570
TX_CURR Age/Sex: 10-14 Female 2017 350
TX_CURR Age/Sex: 10-14 Male 2017 457
TX_CURR Age/Sex: 15-19 Female 2017 940
TX_CURR Age/Sex: 15-19 Male 2017 539
TX_CURR Age/Sex: 20-24 Female 2017 3,968
TX_CURR Age/Sex: 20-24 Male 2017 784
TX_CURR Age/Sex: 25-49 Female 2017 17,303
TX_CURR Age/Sex: 25-49 Male 2017 9,230
TX_CURR Age/Sex: 50+ Female 2017 2,615
TX_CURR Age/Sex: 50+ Male 2017 2,512
TX_CURR Aggregated Age/Sex: <15 Female 2017 6,267
TX_CURR Aggregated Age/Sex: <15 Male 2017 6,590
TX_CURR Aggregated Age/Sex: 15+ Female 2017 120,988
TX_CURR Aggregated Age/Sex: 15+ Male 2017 55,077
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 229,242
TX_CURR Sum of age/sex disaggregates 2017 1,479
TX_CURR Sum of Aggregated Age/Sex <15 2017 12,857
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 176,065
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 188,922
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 2,043
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 1,935
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 28,870
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 14,804
TX_NEW By Age/Sex: <1 2017 52
TX_NEW By Age/Sex: 1-9 2017 452
TX_NEW By Age/Sex: 10-14 Female 2017 64
TX_NEW By Age/Sex: 10-14 Male 2017 74
TX_NEW By Age/Sex: 15-19 Female 2017 530
TX_NEW By Age/Sex: 15-19 Male 2017 175
TX_NEW By Age/Sex: 20-24 Female 2017 1,323
TX_NEW By Age/Sex: 20-24 Male 2017 283
TX_NEW By Age/Sex: 25-49 Female 2017 6,057
TX_NEW By Age/Sex: 25-49 Male 2017 3,491
TX_NEW By Age/Sex: 50+ Female 2017 1,104
TX_NEW By Age/Sex: 50+ Male 2017 1,034
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 62,291
TX_NEW Sum of Age/Sex disaggregates 2017 14,135
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 47,652
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 152,041
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 137,068
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 4,800
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 4,873
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 85,677
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 41,718
TX_PVLS Numerator: Indication: Routine 2017 56,245
TX_PVLS Numerator: Indication: Targeted 2017 80,823
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 5,294
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 5,368
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 95,102
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 46,277
TX_PVLS_den Denominator: Indication: Routine 2017 62,291
TX_PVLS_den Denominator: Indication: Targeted 2017 89,750
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 12
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 168
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 15
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 28
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 175
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 57
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 544
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 107
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,057
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,167
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 356
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 330
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,068
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,010
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 13,319
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,858
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 27,271
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 36,388
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 18
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 222
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 23
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 35
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 231
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 73
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 721
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 145
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,745
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,555
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 471
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 441
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,431
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,348
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 17,785
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 9,144
VMMC_CIRC By Age: 10-14 2017 1,085
VMMC_CIRC By Age: 15-19 2017 1,085
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 2,170
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 2,170
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 2,170
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 2,170
Cross Cutting Budget Categories and Known Amounts Total: $3,858,026
Key Populations: MSM and TG $300,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Key Populations: Sex Workers $300,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Gender: Gender Based Violence (GBV) $658,026
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $600,000
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Human Resources for Health $2,000,000